AEON Biopharma raises $13.75M, with $29.6M more tied to milestones

What's the deal? AEON BiopharmaDealroom has a profile for this one. Try Dealroom → has priced a $13.75 million underwritten public offering, with up to $29.6 million in additional proceeds tied to milestone warrants issued alongside the shares. The offering is expected to close on or about July 15, 2026.

The structure: AEON is selling 42,688,606 shares (or pre-funded warrants) at a combined price of $0.3221, each paired with a two-year and a five-year milestone warrant. Lake Street Capital MarketsDealroom has a profile for this one. Try Dealroom → is sole bookrunner; Laidlaw & Company (UK) is lead manager.

Why now? The NYSE American-listed biopharmaceutical company is developing ABP-450 as a biosimilar to BOTOXDealroom has a profile for this one. Try Dealroom → (onabotulinumtoxinA) for therapeutic use. Proceeds will fund working capital and comparative analytical testing to support biosimilarity to BOTOX.

The warrants: The extra funding is conditional. The two-year warrants expire on the achievement of a specified regulatory milestone for ABP-450; the five-year warrants are tied to a clinical development milestone.

What could go wrong? Only $13.75 million is locked in. The remaining $29.6 million depends on the warrants being exercised in cash — which in turn hinges on AEON hitting its milestones and its share price staying above the exercise levels of $0.3221 and $0.3704.

The signal: AEON's structure reflects how cash-tight small-cap biotechs are stretching modest raises. By tying future capital to regulatory and clinical progress, the company secures runway now while deferring the bulk of potential funding until it can prove ABP-450 is on track.

Image credit: Generated with Gemini